# Vutrisiran Sodium (Amvuttra)

Source: https://ourhealthnetwork.com/drugs/vutrisiran-sodium
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Vutrisiran Sodium?

Vutrisiran Sodium (brand name: Amvuttra) is a small interfering rnas (sirnas). It is prescribed to treat polyneuropathies, amyloid neuropathies, familial.

## Brand names

Amvuttra

## Indications

Vutrisiran Sodium is prescribed for the treatment of polyneuropathies, amyloid neuropathies and familial.

## Conditions treated

- [Polyneuropathies](https://ourhealthnetwork.com/conditions/polyneuropathies)
- [Amyloid Neuropathies](https://ourhealthnetwork.com/conditions/amyloid-neuropathies)
- [Familial](https://ourhealthnetwork.com/conditions/familial)

## Mechanism of action

Vutrisiran is a double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

## Drug classification

- Established Pharmacologic Class: small interfering RNAs (siRNAs)
- Route of administration: SUBCUTANEOUS

## Common side effects

arthralgia, dyspnea, heart block, pain in extremity, vitamin a decreased

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)